This article is more than 5 years old. Information may no longer be current.

PRK study approval tops OSN news

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Here are the top five stories on Healio.com/OSN last week:

FDA approves EyeGate PRK pivotal study

The company’s OBG platform, based on cross-linked thiolated carboxymethyl hyaluronic acid, helps with hydrating and healing the ocular surface. It is suited for ocular surface injuries because it adheres longer to the ocular surface, resists degradation and protects the ocular surface. Read more.

Laserphaco probe inventor Patricia Bath, MD, dies

Patricia Bath, MD, the inventor of the Laserphaco probe and the first black female doctor to patent a medical invention, died from complications from cancer May 30 at the age of 76. Read more.

Aerpio initiates phase 1 trial of AKB-9778 for primary open-angle glaucoma

AKB-9778 binds to and inhibits vascular endothelial protein tyrosine phosphatase, a negative regulator of Tie2. Read more.

Biogen acquires Nightstar Therapeutics

The acquisition adds two mid- to late-stage clinical products — NSR-REP1 for the treatment of choroideremia and NSR-RPGR for the treatment of X-linked retinitis pigmentosa — and preclinical programs to Biogen’s portfolio. Read more.

First patient enrolled in TearCare trial for dry eye

TearCare is a wearable, personalized, open-eye technology that delivers regulated, localized heat to the eyelids. The prospective, multicenter, randomized OLYMPIA study will evaluate TearCare compared with LipiFlow (Johnson & Johnson Vision) in 138 subjects with meibomian gland dysfunction. Read more.